Women’s health
Could this be perimenopause if I still get periods?
A period that arrives early, a hot flush during a meeting, then a month that feels ordinary. The transition can be uneven.

Yes: the transition can begin before periods stop
Perimenopause is the transition leading up to menopause, so continuing to have periods does not rule it out. As hormone levels fluctuate, periods may arrive closer together or farther apart. Night sweats, interrupted sleep and mood changes can also appear. Some women first notice only a different cycle pattern; others notice several changes. Their order and intensity vary, making an uneven experience entirely compatible with this transition. Where does genetics fit? Genes help explain the biology of hormone signaling and ovarian function, but they do not replace the story unfolding in your body. A period arriving early or a hot flush during a meeting is an observation to discuss, not a genetic diagnosis or a reliable countdown to your final period.
Genes are instructions; symptoms are experiences
A gene is a stretch of DNA containing instructions for a functional product, often a protein. A variant is a difference in the DNA sequence; sometimes that difference involves the number of times a short sequence repeats. FMR1 and ESR1 are gene names, not symptoms, diagnoses or predictions. Understanding that distinction makes genetic information less mysterious and more useful. Genotype describes genetic makeup, while phenotype describes observable characteristics, including bodily features or symptoms. Your cycle pattern and night sweats belong to the observable side of that distinction. They do not, by themselves, reveal your genotype. Likewise, knowing a genetic result does not fully describe how you feel or establish where you are in the menopausal transition. Both kinds of information need context.
ESR1: how an estrogen signal is received
ESR1 encodes estrogen receptor alpha, a protein involved in receiving estrogen signals. Hormones need cellular machinery that can respond to them; a receptor provides part of that connection. This is a useful bridge between genetics and everyday experience: genes contribute to the machinery through which hormonal signals act, while perimenopause involves fluctuating hormone levels. The gene and the changing hormone signal are related concepts, not interchangeable measurements. That mechanism does not make ESR1 a personal menopause clock. No single ESR1 variant is a routine calculator of menopause timing, and the cited research does not establish a particular ESR1 variant association. Explaining what a receptor does is different from showing that a specific DNA difference predicts your next period, symptoms or final menstrual date.
FMR1: a specific finding with a different clinical context
FMR1 provides a more specific example of genetic risk. The finding called CGG premutation repeat expansion involves approximately 55–200 repeats of a short DNA sequence. It increases the risk of fragile-X-associated primary ovarian insufficiency, but not everyone carrying the premutation is affected. A repeat count therefore carries risk information, not a guarantee that a particular outcome will occur. Primary ovarian insufficiency, or POI, before age 40 differs from usual perimenopause. This distinction matters: an important finding in an early ovarian-function condition should not turn ordinary questions about changing periods into a rare-disease alarm. Whether genetic testing is indicated is evaluated clinically. FMR1 testing is not a routine tool for predicting menopause, and a changing cycle alone does not establish this genetic finding.
Read genetic evidence without turning risk into destiny
Association means that a finding and an outcome occur together more often in the evidence; causation means that one contributes to producing the other. These are different claims, and neither should be assumed from a gene name alone. The FMR1 premutation is an established risk factor in a specific condition, yet incomplete occurrence among carriers limits individual prediction. ESR1's role in signaling does not itself establish a predictive variant association. For everyday decisions, ask what an observation actually supports. Does it explain a biological pathway, identify increased risk, or establish a clinical condition? Those are different levels of information. A genetic result cannot substitute for discussing symptoms, age and menstrual history, and symptoms cannot identify a particular DNA variant without appropriate testing.
The calendar matters, but you need not wait for help
If you are not using hormonal contraception, menopause is generally identified after 12 months without a period when there is no other cause. Perimenopause comes before that point, so disruptive symptoms deserve attention even while periods continue. If bleeding returns after those 12 months, even light spotting deserves a medical check. A gene result does not replace this assessment of what is happening clinically. Keep the conversation grounded in daily life: an interrupted night, a meeting disrupted by heat, or a cycle that has changed from your usual pattern. These details describe your phenotype more directly than a gene name does. They also give the clinician a starting point for considering your circumstances, rather than treating a genetic possibility as an explanation already established.
Sources & further reading
- NHS · Menopause and perimenopause ↗
- MedlinePlus Genetics · FMR1 gene ↗
- MedlinePlus Genetics · Fragile-X-associated primary ovarian insufficiency ↗
- NCBI Gene · ESR1, estrogen receptor 1 ↗
Educational reading to enrich your conversation with a healthcare professional, interpreted in the context of your own health and needs.
